ABSTRACT In response to the problems of high impurity content in ears and poor stalk crushing efficiency during the harvesting of fresh corn, a double fan high-pressure impurity removal and cleaning device was designed based on the operating conditions and mechanical analysis of harvester. Field trials were conducted using fan speed (1200 rpm, 1300 rpm and 1400 rpm) and harvester operating speed (6 km/h, 8 km/h and 10 km/h) as test conditions, with ear impurity content rate and stalk crushing length qualification rate as indicators. Ear impurity content rate ranged from 0.25% to 0.50% and stalk crushing length qualification rate ranged from 96.1% to 98.6%, with test results meeting operation standard under all test conditions. The designed device was able to meet the operational requirements.

OBJECTIVES: Timolol maleate has been reported to be a safer intraocular pressure (IOP) lowering treatment than latanoprost. The United States Food and Drug Administration approved latanoprostene bunod, a nitric oxide-donating prodrug of latanoprost, for lowering IOP. This study compared the safety and efficacy of latanoprost, latanoprostene bunod, and timolol maleate in patients with open-angle glaucoma. METHODS: Patients who received latanoprost eye drops once daily in the evening were included in the latanoprost Ophthalmic Solutions (LP) cohort (n=104). Those who received latanoprostene bunod eye drops once daily in the evening were included in the Latanoprostene Bunod (LB) cohort (n=94). Those who received timolol eye drops twice daily were included in the Timolol Maleate (TM) cohort (n=115). All treatments were administered to the affected eye(s) for 3 months. Informed Consent has been taken from each participant before the trial. RESULTS: At the end of 3 months of treatment, latanoprost, latanoprostene bunod, and timolol were all successful in reducing IOP. The LB cohort had the highest reduction in IOP, compared to the LP and TM cohorts. All treatments had some common adverse ocular effects. CONCLUSION: Latanoprostene bunod was superior to latanoprost and timolol for the treatment of open-angle glaucoma.